NCT04204057 2024-08-13Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Rhizen Pharmaceuticals SAPhase 2 Completed21 enrolled 12 charts
NCT03711604 2024-05-08Compassionate Use Study of Tenalisib (RP6530)Rhizen Pharmaceuticals SAPhase 1/2 Completed17 enrolled 9 charts